Literature DB >> 29759351

Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia.

Glenn T Konopaske1, Darrick T Balu2, Kendall T Presti3, Grace Chan4, Francine M Benes2, Joseph T Coyle2.   

Abstract

Deep layer III pyramidal cells in the dorsolateral prefrontal cortex (DLPFC) from subjects with schizophrenia and bipolar disorder previously were shown to exhibit dendritic arbor pathology. This study sought to determine whether MARCKS, its regulatory protein dysbindin-1, and two proteins, identified using microarray data, CDC42BPA and ARHGEF6, were associated with dendritic arbor pathology in the DLPFC from schizophrenia and bipolar disorder subjects. Using western blotting, relative protein expression was assessed in the DLPFC (BA 46) grey matter from subjects with schizophrenia (n = 19), bipolar disorder (n = 17) and unaffected control subjects (n = 19). Protein expression data were then correlated with dendritic parameter data obtained previously. MARCKS and dysbindin-1a expression levels did not differ among the three groups. Dysbindin-1b expression was 26% higher in schizophrenia subjects (p = 0.01) and correlated inversely with basilar dendrite length (r = -0.31, p = 0.048) and the number of spines per basilar dendrite (r = -0.31, p = 0.048), but not with dendritic spine density (r = -0.16, p = 0.32). The protein expression of CDC42BPA was 33% higher in schizophrenia subjects (p = 0.03) but, did not correlate with any dendritic parameter (p > 0.05). ARHGEF6 87 kDa isoform expression did not differ among the groups. CDC42BPA expression was not altered in frontal cortex from rats chronically administered haloperidol or clozapine. Dysbindin-1b appears to play a role in dendritic arbor pathology observed previously in the DLPFC in schizophrenia.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Dendrite; Dysbindin-1; Postmortem; Schizophrenia; Western blot

Mesh:

Substances:

Year:  2018        PMID: 29759351      PMCID: PMC6230503          DOI: 10.1016/j.schres.2018.04.042

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  60 in total

1.  Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain.

Authors:  M A Benson; S E Newey; E Martin-Rendon; R Hawkes; D J Blake
Journal:  J Biol Chem       Date:  2001-04-20       Impact factor: 5.157

2.  Altered prefrontal cortical MARCKS and PPP1R9A mRNA expression in schizophrenia and bipolar disorder.

Authors:  Glenn T Konopaske; Sivan Subburaju; Joseph T Coyle; Francine M Benes
Journal:  Schizophr Res       Date:  2015-03-07       Impact factor: 4.939

3.  Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42 effector in promoting cytoskeletal reorganization.

Authors:  T Leung; X Q Chen; I Tan; E Manser; L Lim
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

4.  Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia.

Authors:  Dibyadeep Datta; Dominique Arion; John P Corradi; David A Lewis
Journal:  Biol Psychiatry       Date:  2015-04-11       Impact factor: 13.382

5.  Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization.

Authors:  Yukihiko Iizuka; Yoshitatsu Sei; Daniel R Weinberger; Richard E Straub
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

6.  Molecular evidence for mitochondrial dysfunction in bipolar disorder.

Authors:  Christine Konradi; Molly Eaton; Matthew L MacDonald; John Walsh; Francine M Benes; Stephan Heckers
Journal:  Arch Gen Psychiatry       Date:  2004-03

7.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia.

Authors:  Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

8.  The pathogenic mechanism of dysbindin-1B toxic aggregation: BLOC-1 and intercellular vesicle trafficking.

Authors:  Wei Yang; Chunyan Zhu; Yan Shen; Qi Xu
Journal:  Neuroscience       Date:  2016-07-12       Impact factor: 3.590

9.  The N-ethylmaleimide-sensitive factor and dysbindin interact to modulate synaptic plasticity.

Authors:  Avanti Gokhale; Ariana P Mullin; Stephanie A Zlatic; Charles A Easley; Megan E Merritt; Nisha Raj; Jennifer Larimore; David E Gordon; Andrew A Peden; Subhabrata Sanyal; Victor Faundez
Journal:  J Neurosci       Date:  2015-05-13       Impact factor: 6.167

10.  Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice.

Authors:  James David Jentsch; Heather Trantham-Davidson; Corey Jairl; Matthew Tinsley; Tyrone D Cannon; Antonieta Lavin
Journal:  Neuropsychopharmacology       Date:  2009-07-29       Impact factor: 7.853

View more
  5 in total

1.  Risperidone Ameliorates Prefrontal Cortex Neural Atrophy and Oxidative/Nitrosative Stress in Brain and Peripheral Blood of Rats with Neonatal Ventral Hippocampus Lesion.

Authors:  Hiram Tendilla-Beltrán; Silvia Meneses-Prado; Rubén Antonio Vázquez-Roque; Miguel Tapia-Rodríguez; Andrea Judith Vázquez-Hernández; Heriberto Coatl-Cuaya; David Martín-Hernández; Karina S MacDowell; Linda Garcés-Ramírez; Juan C Leza; Gonzalo Flores
Journal:  J Neurosci       Date:  2019-09-13       Impact factor: 6.167

2.  Cortical copper transporter expression in schizophrenia: interactions of risk gene dysbindin-1.

Authors:  Kirsten E Schoonover; William M Kennedy; Rosalinda C Roberts
Journal:  J Neural Transm (Vienna)       Date:  2021-04-22       Impact factor: 3.575

3.  Classification for psychiatric disorders including schizophrenia, bipolar disorder, and major depressive disorder using machine learning.

Authors:  Qingxia Yang; Qiaowen Xing; Qingfang Yang; Yaguo Gong
Journal:  Comput Struct Biotechnol J       Date:  2022-09-12       Impact factor: 6.155

Review 4.  Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond.

Authors:  John L Waddington; Xuechu Zhen; Colm M P O'Tuathaigh
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

5.  Clustering by phenotype and genome-wide association study in autism.

Authors:  Akira Narita; Masato Nagai; Satoshi Mizuno; Soichi Ogishima; Gen Tamiya; Masao Ueki; Rieko Sakurai; Satoshi Makino; Taku Obara; Mami Ishikuro; Chizuru Yamanaka; Hiroko Matsubara; Yasutaka Kuniyoshi; Keiko Murakami; Fumihiko Ueno; Aoi Noda; Tomoko Kobayashi; Mika Kobayashi; Takuma Usuzaki; Hisashi Ohseto; Atsushi Hozawa; Masahiro Kikuya; Hirohito Metoki; Shigeo Kure; Shinichi Kuriyama
Journal:  Transl Psychiatry       Date:  2020-08-17       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.